While anti‐PD‐1 and anti‐PD‐L1 therapies have shown promise in recurrent and metastatic HNSCC,[2, 3] improving overall response rates remains a critical challenge. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.